DoxorubicinCyclophosphamideAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsCombined Modality TherapyAntineoplastic AgentsCisplatinCell Line, TumorRemission InductionChemotherapy, AdjuvantTreatment OutcomeDrug Resistance, NeoplasmBreast NeoplasmsPaclitaxelVincristineDisease-Free SurvivalDrug Administration ScheduleApoptosisCaspase 12EtoposideSurvival AnalysisTumor Suppressor Protein p53Survival RateFluorouracilNeoadjuvant TherapyNeoplasm StagingLung NeoplasmsAntineoplastic Agents, PhytogenicMethotrexateCytarabineCarboplatinHead and Neck NeoplasmsIfosfamideCarcinoma, Squamous CellPrednisonePrognosisCardiomyopathiesDaunorubicinDose-Response Relationship, DrugVinblastineAntineoplastic Agents, AlkylatingNeutropeniaLeukemia, Myeloid, AcuteMitochondria, HeartNeoplasm MetastasisDNA DamageDeoxycytidineTime FactorsCarcinoma, Non-Small-Cell LungNeoplasm Recurrence, LocalGranulocyte Colony-Stimulating FactorEpirubicinTumor Markers, BiologicalBleomycinLeukopeniaHeartRNA, MessengerMyocardiumGene Expression Regulation, NeoplasticMitoxantroneFollow-Up StudiesRNA, Small InterferingSignal TransductionTransplantation, AutologousRadiotherapy, AdjuvantAdenocarcinomaPhosphoramide MustardsInfusions, IntravenousPrecursor Cell Lymphoblastic Leukemia-LymphomaSalvage TherapyMelphalanThiotepaKaplan-Meier EstimateTumor BurdenNeoplasmsEnzyme InductionRadiotherapyAnthracyclinesLymphoma, Non-HodgkinChemoradiotherapyRadiotherapy DosageBone NeoplasmsProspective StudiesIdarubicinDisease ProgressionHematopoietic Stem Cell TransplantationAntibodies, MonoclonalLeukemia, MyeloidAntimetabolites, AntineoplasticLymphatic MetastasisOvarian NeoplasmsTumor Necrosis Factor-alphaHypopharyngeal NeoplasmsMesnaRecurrenceBrain NeoplasmsLaryngectomyP-Glycoprotein